Some notable properties of the standard oncology phase I design
Applications
2009-06-08 v2
Abstract
We identify three properties of the standard oncology phase I trial design or 3 + 3 design. We show that the standard design implicitly uses isotonic regression to estimate a maximum tolerated dose. We next illustrate the relationship between the standard design and a Bayesian design proposed by Ji et al. (2007). A slight modification to this Bayesian design, under a particular model specification, would assign treatments in a manner identical to the standard design. We finally present calculations revealing the behavior of the standard design in a worst case scenario and compare its behavior with other 3 + 3-like designs.
Keywords
Cite
@article{arxiv.0808.0359,
title = {Some notable properties of the standard oncology phase I design},
author = {Gregory J. Hather and Howard Mackey},
journal= {arXiv preprint arXiv:0808.0359},
year = {2009}
}